Make me comparative table for all rickettsiae infection
Reading File
Now let me search the medical library for rickettsial infections comprehensively.
Finding Sources
Finding Sources
Good findings. Now let me read the most comprehensive sources - Harrison's, Jawetz, and Goldman-Cecil for rickettsial disease tables.
Reading File
Reading File
Reading File
Excellent - I have very rich data from Harrison's. Let me read more of that block for the detailed disease-by-disease content, plus the Goldman-Cecil table.
Reading File
Reading File
I now have very rich data from Harrison's (block21) which contains a comprehensive Table 192-1. Let me read more to get the full clinical details for all rickettsial diseases.
Reading File
Reading File
I have extensive data from Harrison's block21 already (the large truncated result contained the full disease table). I now have enough information to compile a comprehensive comparative table. Let me now construct it from all the data gathered.
Based on Harrison's 22nd edition, Goldman-Cecil, Jawetz, and Henry's Lab Diagnosis, here is the comprehensive comparative table:
Comparative Table of All Rickettsial Infections
The organisms below belong to 7 genera: Rickettsia, Orientia, Ehrlichia, Anaplasma, Neorickettsia, "Candidatus Neoehrlichia", and Coxiella.
Group 1: Spotted Fever Group Rickettsiae (SFGR)
| Feature | Rocky Mountain Spotted Fever (RMSF) | Mediterranean Spotted Fever (MSF) / Boutonneuse Fever | African Tick-Bite Fever | Rickettsialpox | R. parkeri Infection | Pacific Coast Tick Fever |
|---|---|---|---|---|---|---|
| Organism | R. rickettsii | R. conorii | R. africae | R. akari | R. parkeri | R. philipii |
| Vector | Dermacentor ticks (wood/dog tick); also Amblyomma cajennense | Rhipicephalus sanguineus (brown dog tick) | Amblyomma hebraeum, A. variegatum | Liponyssoides sanguineus (mouse mite) | Amblyomma maculatum (Gulf Coast tick) | Dermacentor occidentalis (Pacific Coast tick) |
| Reservoir | Ticks (transovarial); small mammals | Dog tick; dogs, rodents | Cattle, ruminants | House mice | Rodents, cattle | Unknown |
| Geography | Americas (SE/SC USA most common; Brazil, Colombia, Mexico, Argentina) | Mediterranean basin, Southern Europe, Africa, Middle East, India | Sub-Saharan Africa, Caribbean | Eastern USA, former USSR | SE USA, Gulf Coast | Pacific Coast USA |
| Incubation | 2-14 days (mean 7 days) | 5-7 days | 5-7 days | 10-17 days | ~7 days | ~7 days |
| Fever | Yes, abrupt onset | Yes, high | Yes | Yes | Yes | Yes |
| Rash | Maculopapular → petechial; starts wrists/ankles → trunk; involves palms/soles | Maculopapular; involves palms/soles | Multiple vesicular/papular lesions; often multiple eschars | Papulovesicular rash (like chickenpox) | Maculopapular/vesicular | Maculopapular |
| Eschar | Rarely present | Often single eschar ("tache noire") | Multiple eschars (hallmark) | Papule → eschar at bite site | Eschar present | Variable |
| Severity | Most severe SFGR; case fatality ~20-25% untreated; up to 73% in some outbreaks | Moderate-severe; ~2-3% CFR | Usually mild-moderate | Mild, self-limited | Mild-moderate | Mild |
| Pathology | Endothelial cell invasion → vasculitis, microvascular injury, increased permeability | Endothelial vasculitis | Endothelial vasculitis | Endothelial vasculitis | Endothelial vasculitis | Endothelial vasculitis |
| Intracellular location | Cytoplasm and nucleus | Cytoplasm and nucleus | Cytoplasm and nucleus | Cytoplasm and nucleus | Cytoplasm and nucleus | Cytoplasm and nucleus |
| Lab findings | Thrombocytopenia, hyponatremia, elevated LFTs, normal/low WBC | Thrombocytopenia, elevated LFTs | Usually mild changes | Mild thrombocytopenia | Similar to RMSF but milder | Similar to RMSF |
| Diagnosis | Clinical + DFA on skin biopsy; PCR; serology (IFA - 4-fold rise) | IFA serology; PCR; skin biopsy | Clinical + IFA; PCR from eschar swab | IFA serology; PCR | PCR; IFA serology | PCR; IFA serology |
| Treatment | Doxycycline 100 mg BID x 5-7 days (DOC); chloramphenicol in pregnancy | Doxycycline 100 mg BID x 5-7 days | Doxycycline 100 mg BID x 5-7 days | Doxycycline | Doxycycline | Doxycycline |
| Notes | Sulfonamides worsen disease; do not delay treatment; bioterrorism agent | "Tache noire" is pathognomonic | Multiple bite sites, multiple eschars distinguish from MSF | Vesicular rash mimics varicella | Milder phenotype vs. RMSF | Pacific Coast only |
Group 2: Typhus Group Rickettsiae
| Feature | Epidemic (Louse-borne) Typhus | Brill-Zinsser Disease | Murine (Endemic) Typhus | Scrub Typhus |
|---|---|---|---|---|
| Organism | R. prowazekii | R. prowazekii (reactivation) | R. typhi | Orientia tsutsugamushi |
| Vector/Transmission | Human body louse (Pediculus humanus) - feces inoculated by scratching | Reactivation (no vector needed) | Oriental rat flea (Xenopsylla cheopis) - feces inoculated | Larval trombiculid mites (Leptotrombidium spp.) - chigger bite |
| Reservoir | Humans (only rickettsial disease where humans are primary reservoir) | Previous host (the patient themselves) | Rats (Rattus spp.) | Rodents; mites serve as reservoir AND vector (transovarial) |
| Geography | Africa, South America, Asia; war/famine/disaster zones; cold climates | Worldwide (prior louse typhus areas) | Worldwide; seaports, tropical/subtropical | Asia-Pacific region ("scrub typhus belt"); NE Australia; parts of Africa |
| Incubation | 7-14 days | Weeks to decades after primary episode | 7-14 days (mean 11 days) | 6-21 days (mean 10-12 days) |
| Fever | Sudden onset, high (39-41°C), sustained | Milder than primary episode | Gradual onset (3-day prodrome) | Abrupt onset, high |
| Rash | Maculopapular → petechial; starts trunk → extremities; spares face/palms/soles | Macular or maculopapular, milder | Maculopapular; similar to epidemic typhus but milder | Maculopapular (in ~50%); trunk → extremities |
| Eschar | Absent | Absent | Absent | Present at chigger bite site (pathognomonic when found, ~50% of cases) |
| Severity | Severe; CFR 10-40% without treatment; higher in elderly | Milder than primary; CFR <1% | Moderate; CFR <1% with treatment; ~1-4% untreated | Moderate-severe; variable by strain; CFR 1-30% without treatment |
| Complications | Meningoencephalitis, pneumonitis, myocarditis, vasculitis, gangrene | Same complications as primary, but milder | Pneumonitis, hepatitis, meningoencephalitis | Interstitial pneumonitis, meningoencephalitis, myocarditis, acute renal failure |
| Pathology | Vasculitis, endothelial involvement, grows in cytoplasm | Same as epidemic typhus | Vasculitis; grows in cytoplasm | Endothelial cell invasion; lymphadenopathy (generalized) |
| Intracellular location | Cytoplasm | Cytoplasm | Cytoplasm | Cytoplasm |
| Lab findings | Thrombocytopenia, elevated LFTs, hyponatremia, elevated ESR | Mild thrombocytopenia, elevated ESR | Thrombocytopenia, elevated LFTs, anemia | Thrombocytopenia, elevated LFTs, hyponatremia, hypoalbuminemia |
| Serology | Weil-Felix (OX-19 positive); IFA (gold standard) | IFA (lower titers than primary) | Weil-Felix (OX-19 positive); IFA | Weil-Felix (OX-K positive); IFA (limited by antigenic variation of O. tsutsugamushi) |
| Diagnosis | Clinical + IFA; PCR; skin biopsy | Clinical history of prior typhus + milder illness; IFA | IFA serology; PCR | Eschar + clinical picture; IFA; PCR from eschar or blood |
| Treatment | Doxycycline 100 mg BID x 7-14 days (single 200 mg dose also effective); chloramphenicol | Doxycycline; single dose often sufficient | Doxycycline 100 mg BID x 7 days; also responds to azithromycin | Doxycycline 100 mg BID x 7-15 days; azithromycin (preferred in pregnancy & children) |
| Notes | Only rickettsial disease transmitted human-to-human (via lice); bioterrorism threat; associated with war/poverty/crowding | Latent form of epidemic typhus reactivated by stress/immunosuppression (recrudescence after years) | Flying squirrels also reservoir in SE USA (R. prowazekii variant) | Largest rickettsial disease burden globally; azithromycin emerging for doxycycline-resistant strains |
Group 3: Ehrlichioses & Anaplasmosis (Family Anaplasmataceae)
| Feature | Human Monocytotropic Ehrlichiosis (HME) | Human Granulocytotropic Anaplasmosis (HGA) | Ehrlichia ewingii Infection | Neoehrlichiosis |
|---|---|---|---|---|
| Organism | Ehrlichia chaffeensis | Anaplasma phagocytophilum | Ehrlichia ewingii | "Candidatus Neoehrlichia mikurensis" |
| Target cell | Monocytes/macrophages (morulae in cytoplasm) | Granulocytes/neutrophils (morulae in cytoplasm) | Granulocytes | Endothelial cells / macrophages |
| Vector | Amblyomma americanum (lone star tick) | Ixodes scapularis (black-legged tick); I. pacificus (West Coast) | Amblyomma americanum | Ixodes ricinus (Europe) |
| Reservoir | White-tailed deer | White-footed mouse, white-tailed deer | White-tailed deer | Rodents |
| Geography | SE and SC USA (overlaps with Lone Star tick range) | NE and Upper Midwest USA; Pacific Coast; Europe; Asia | SE USA | Europe (esp. immunocompromised patients) |
| Incubation | 5-21 days (mean 9 days) | 5-21 days (mean ~9 days) | 5-21 days | Variable (weeks) |
| Fever | Abrupt, high | Abrupt, high | Yes | Yes |
| Rash | In ~36% (more common than HGA) | In <10% (rare - should prompt reconsidering diagnosis) | Occasional | Rare |
| Eschar | Absent | Absent | Absent | Absent |
| Morulae on smear | Present in monocytes (~4%) | Present in neutrophils (~20-80%) | Present in granulocytes | Not typically seen |
| Severity | Moderate-severe; CFR ~2-3%; severe in immunocompromised | Moderate; CFR <1%; can be severe in elderly/immunocompromised | Mild-moderate | Severe in immunocompromised; can be fatal |
| Complications | Meningoencephalitis, respiratory failure, opportunistic infections (due to immunosuppression of monocytes) | DIC, respiratory failure; may unmask HIV; rarely neurologic | Usually mild | Thromboembolic events, fever, weight loss |
| Lab findings | Leukopenia, thrombocytopenia, elevated LFTs, elevated ESR | Leukopenia + neutropenia, thrombocytopenia, elevated LFTs, anemia | Leukopenia, thrombocytopenia | Elevated inflammatory markers; variable cytopenias |
| Serology | IFA (paired sera); PCR on blood (gold standard in acute phase) | IFA; PCR on blood (gold standard); blood smear | PCR; IFA | PCR; 16S rRNA gene sequencing |
| Treatment | Doxycycline 100 mg BID x 5-10 days | Doxycycline 100 mg BID x 5-10 days | Doxycycline | Doxycycline; rifampin alternative |
| Notes | No rash: "spotless" infection; common in immunocompromised; can cause life-threatening opportunistic infections | Ixodes tick also transmits Lyme disease and babesiosis - co-infection possible | Clinically mild vs. HME | Mainly in splenectomized or immunocompromised patients in Europe |
Group 4: Q Fever (Family Coxiellaceae)
| Feature | Acute Q Fever | Chronic Q Fever |
|---|---|---|
| Organism | Coxiella burnetii | Coxiella burnetii |
| Transmission | Inhalation of aerosols from infected animals (especially parturient livestock - cattle, sheep, goats); raw milk; rarely tick bite (Amblyomma, Dermacentor) | Persistence of primary infection |
| Reservoir | Cattle, sheep, goats; cats; ticks | Same host |
| Geography | Worldwide (except New Zealand) | Worldwide |
| Incubation | 2-6 weeks (dose-dependent) | Months to years after acute infection |
| Fever | Yes, abrupt, high | Low-grade or absent |
| Rash | In ~17% (maculopapular) | Rare |
| Eschar | Absent | Absent |
| Clinical Presentation | Self-limited febrile illness; atypical pneumonia (50-60%); hepatitis (granulomatous hepatitis with "doughnut granuloma"); can present as isolated fever | Endocarditis (most common - ~60-70% of chronic Q fever); hepatitis; osteomyelitis; vascular infections; chronic fatigue syndrome |
| Severity | Usually self-limited; <1% CFR | High mortality (25-65%) without treatment; requires prolonged therapy |
| Pathology | Intracellular in phagolysosome (acidic vacuole - unique among rickettsiae); induces phase variation (Phase I - virulent; Phase II - avirulent) | Endovascular infection; immune complex deposition |
| Lab findings | Elevated LFTs, elevated ESR, thrombocytopenia; CXR: patchy consolidation | Elevated Phase I IgG (≥1:800 by IFA) - diagnostic hallmark |
| Serology | Phase II antibodies predominate in acute; Phase I antibodies predominate in chronic | Phase I IgG ≥1:800 (diagnostic of chronic Q fever) |
| Diagnosis | Clinical + PCR (acute phase); serology (acute vs. convalescent IFA); Weil-Felix negative | Serology (Phase I IgG ≥1:800); PCR; echocardiography |
| Treatment (Acute) | Doxycycline 100 mg BID x 14 days | - |
| Treatment (Chronic) | - | Doxycycline 100 mg BID + hydroxychloroquine 200 mg TID x 18-24 months (DOC); monitor doxycycline levels; ophthalmology follow-up |
| Notes | Single organism can cause infection; bioterrorism threat; "atypical" appearance on CXR; granulomatous hepatitis ("doughnut granuloma" or fibrin-ring granuloma is hallmark); sulfonamides NOT harmful (unlike other rickettsiae) | Prophylaxis with doxycycline + hydroxychloroquine in patients with valvular disease after acute Q fever; check Phase I serology at 6 months post-acute |
Group 5: Neorickettsia
| Feature | Sennetsu Fever |
|---|---|
| Organism | Neorickettsia sennetsu |
| Vector/Transmission | Ingestion of raw fish containing infected metacercariae (fish-borne trematode) |
| Geography | Japan, Malaysia |
| Clinical features | Infectious mononucleosis-like illness: fever, lymphadenopathy (posterior cervical most prominent), malaise, anorexia |
| Rash | Absent |
| Treatment | Doxycycline |
| Notes | No arthropod vector; only food-borne rickettsial disease |
Quick-Reference Summary Table
| Disease | Organism | Group | Vector | Eschar | Rash | Morulae | Weil-Felix | Treatment |
|---|---|---|---|---|---|---|---|---|
| RMSF | R. rickettsii | Spotted fever | Tick | Rare | Yes (palms/soles) | No | OX-19, OX-2 | Doxycycline |
| Mediterranean SF | R. conorii | Spotted fever | Tick | Yes (tache noire) | Yes (palms/soles) | No | OX-19, OX-2 | Doxycycline |
| African tick-bite fever | R. africae | Spotted fever | Tick | Multiple | Yes (vesicular) | No | OX-19, OX-2 | Doxycycline |
| Rickettsialpox | R. akari | Spotted fever | Mite | Yes | Yes (vesicular) | No | Negative | Doxycycline |
| R. parkeri infection | R. parkeri | Spotted fever | Tick | Yes | Yes | No | OX-19, OX-2 | Doxycycline |
| Epidemic typhus | R. prowazekii | Typhus | Body louse | No | Yes (trunk first) | No | OX-19 | Doxycycline |
| Brill-Zinsser | R. prowazekii | Typhus | None (reactivation) | No | Mild/variable | No | OX-19 (low) | Doxycycline |
| Murine typhus | R. typhi | Typhus | Rat flea | No | Yes (trunk first) | No | OX-19 | Doxycycline |
| Scrub typhus | O. tsutsugamushi | Scrub typhus | Mite (chigger) | Yes (~50%) | Yes (~50%) | No | OX-K | Doxycycline / Azithromycin |
| HME | E. chaffeensis | Ehrlichiosis | Lone star tick | No | Yes (~36%) | Monocytes | Negative | Doxycycline |
| HGA | A. phagocytophilum | Anaplasmosis | Ixodes tick | No | Rare (<10%) | Neutrophils | Negative | Doxycycline |
| E. ewingii | E. ewingii | Ehrlichiosis | Lone star tick | No | Rare | Granulocytes | Negative | Doxycycline |
| Neoehrlichiosis | "Ca." N. mikurensis | Ehrlichiosis | Ixodes tick | No | Rare | No | Negative | Doxycycline |
| Q fever (acute) | C. burnetii | Coxiella | Aerosol/tick | No | Rare (17%) | No | Negative | Doxycycline |
| Q fever (chronic) | C. burnetii | Coxiella | - | No | No | No | Negative | Doxycycline + Hydroxychloroquine |
| Sennetsu fever | N. sennetsu | Neorickettsia | Raw fish | No | No | No | Negative | Doxycycline |
Key Points
-
Doxycycline is the drug of choice for virtually all rickettsial infections. Delay in treatment significantly worsens outcomes - especially in RMSF and epidemic typhus.
-
Sulfonamides are contraindicated in most rickettsial infections as they enhance rickettsial growth and worsen disease. Exception: TMP-SMX is used in Q fever during pregnancy (doxycycline is relatively contraindicated in pregnancy for most other rickettsiae; azithromycin is used for scrub typhus in pregnancy).
-
Weil-Felix reaction (agglutination of Proteus strains): OX-19 & OX-2 positive in spotted fever group and typhus group; OX-K positive in scrub typhus; negative in Q fever, ehrlichioses, rickettsialpox.
-
Chronic illness occurs only with C. burnetii (Q fever endocarditis). Recrudescence (not true chronicity) occurs with R. prowazekii (Brill-Zinsser disease).
-
Bioterrorism agents: R. prowazekii, R. rickettsii, R. typhi, R. conorii, and C. burnetii.
-
Laboratory clues common to most rickettsial infections: thrombocytopenia + elevated LFTs + normal/low WBC + hyponatremia in the right clinical/epidemiological context.
- Harrison's Principles of Internal Medicine 22e, Chapter 192 (Rickettsial Diseases)
- Goldman-Cecil Medicine, Chapter 302 (Rickettsial Infections)
- Jawetz, Melnick & Adelberg's Medical Microbiology 28e, Chapter 26
- Henry's Clinical Diagnosis and Management by Laboratory Methods, Chapter 63
This is a shared conversation. Sign in to Orris to start your own chat.